DS-3201b + DS-3201b
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Malignant
Conditions
Lymphoma, Malignant, Non-hodgkin Lymphoma
Trial Timeline
Mar 31, 2016 → Dec 31, 2026
NCT ID
NCT02732275About DS-3201b + DS-3201b
DS-3201b + DS-3201b is a phase 1 stage product being developed by Daiichi Sankyo for Lymphoma, Malignant. The current trial status is active. This product is registered under clinical trial identifier NCT02732275. Target conditions include Lymphoma, Malignant, Non-hodgkin Lymphoma.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Malignant were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02732275 | Phase 1 | Active |
Competing Products
20 competing products in Lymphoma, Malignant